Navigation Links
Proteolix Initiates Multicenter Open-label Study of the Safety and Activity of Carfilzomib in Subjects With Relapsed Solid Tumors
Date:10/10/2007

Phase 1b/2 Study to Explore the Efficacy of Novel Proteasome Inhibitor in

Patients with Relapsed Solid Tumors

SOUTH SAN FRANCISCO, Calif., and SAN ANTONIO, Oct. 10 /PRNewswire/ -- Proteolix, Inc. and South Texas Accelerated Research Therapeutics (START) today announced the enrollment of the first patient in a Phase 1 clinical trial to study Proteolix's investigational drug, carfilzomib (PR-171). START is participating in the study under the leadership of Kyriakos Papadopoulos, M.D., MSc, FCP(SA).

This trial is evaluating single agent carfilzomib, a novel proteasome inhibitor, in patients with recurrent or advanced solid tumors. The Phase 1b portion of the study is a dose-escalation study designed to determine the maximum tolerated dose of carfilzomib administered intravenously in patients with solid tumors. After determining the maximum tolerated dose, additional patients will be enrolled in Phase 2 and stratified according to disease type, including non-small cell lung cancer, small cell lung cancer, ovarian cancer and renal cancer.

"We are very excited about beginning this study in San Antonio. This next generation proteasome inhibitor has shown promising activity in myeloma and will offer a new option to our patients with advanced cancer," said Dr. Papadopoulos.

About Carfilzomib

Carfilzomib is a structurally- and mechanistically-novel proteasome inhibitor that exhibits a high level of selectivity for a single active site in the proteasome with minimal cross reactivity to other protease classes. Carfilzomib has been shown in both preclinical and clinical studies to be well tolerated on intensive daily dosing schedules; in preclinical models, this intensive dosing results in greatly improved efficacy against solid tumors. Phase 1 clinical studies have shown that patients with hematologic malignancies who have relapsed or progressed following multiple therapies can achieve durable anti-tumor responses with ca
'/>"/>

SOURCE Proteolix, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Malvern initiates European user group meetings for chemical imaging
2. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
3. Accera, Inc. Announces Open-Label Data from Phase II Study in Alzheimers Disease at International Conference on Prevention of Dementia
4. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
5. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
6. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2008)...development and validation of non-animal alternati... MatTek Corporation today announce...AC) endorsed the scientific validity of the Modifi...ber meeting. ESAC concluded that the Modified Epi...or the prediction of skin irritating and non-irrit...
(Date:12/17/2008)... of Its Kind; 80 Percent of Trauma Patient,s Face ...wire/ -- A multi-disciplinary team of doctors and ...e first near-total face transplant in the United...ed within the past two weeks, surgeons transplante... facial trauma -- essentially replacing her entire...
(Date:12/17/2008)...swire-FirstCall/ -- Medivation, Inc.,(Nasdaq: M...t enrollment in a,Phase 1-2 dose-escalation clini... antagonist, in castration-resistant prostate canc...the U.S. Food and Drug Administration (FDA) to,ad... The open-label, U.S. Phase 1-2 study evaluated ...
(Date:12/17/2008)... December 17 NicOx,S.A....ve results of a,pre-specified pooled analysis of ...301, 302 and 303 pivotal phase 3 studies for napro...icant reduction in systolic and diastolic blood,p...bid over the whole 13 week,period (p<0.001 for...
Breaking Medicine Technology:EpiDerm's Skin Irritation Test Fully Validated in European Union 2Cleveland Clinic Surgeons Perform Nation's First Near-Total Face Transplant 2Cleveland Clinic Surgeons Perform Nation's First Near-Total Face Transplant 3Medivation Completes Enrollment of Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients 2Medivation Completes Enrollment of Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients 3Medivation Completes Enrollment of Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients 4NicOx' Naproxcinod Shows Robust Blood Pressure Results in Phase 3 Pooled Analysis 2NicOx' Naproxcinod Shows Robust Blood Pressure Results in Phase 3 Pooled Analysis 3NicOx' Naproxcinod Shows Robust Blood Pressure Results in Phase 3 Pooled Analysis 4NicOx' Naproxcinod Shows Robust Blood Pressure Results in Phase 3 Pooled Analysis 5Lead Exposure in Childhood Linked to Criminal Behavior Later 20416 1Lead Exposure in Childhood Linked to Criminal Behavior Later 20416 2Lead Exposure in Childhood Linked to Criminal Behavior Later 20416 3Study shows pine bark naturally reduces cardiovascular risk factors in diabetics 20414 1Study shows pine bark naturally reduces cardiovascular risk factors in diabetics 20414 2Study shows pine bark naturally reduces cardiovascular risk factors in diabetics 20414 3Atherotech to Exhibit The VAP Test at ADA 2008 Meeting in San Francisco 20409 1Atherotech to Exhibit The VAP Test at ADA 2008 Meeting in San Francisco 20409 2Streamline Healths Document Management Solution Integrated into Oacis Allowing Clinicians to Access Patients Information Either Scanned or Electron 20403 1Streamline Healths Document Management Solution Integrated into Oacis Allowing Clinicians to Access Patients Information Either Scanned or Electron 20403 2Streamline Healths Document Management Solution Integrated into Oacis Allowing Clinicians to Access Patients Information Either Scanned or Electron 20403 3Streamline Healths Document Management Solution Integrated into Oacis Allowing Clinicians to Access Patients Information Either Scanned or Electron 20403 4Streamline Healths Document Management Solution Integrated into Oacis Allowing Clinicians to Access Patients Information Either Scanned or Electron 20403 5
... 19, 2007 - Aeolus,Pharmaceuticals, Inc. (OTCBB:AO...ers at Loma Linda University Medical Center,Natio...iversity,showing that one of the Company,s metallo...rotection of healthy normal cells in mice,with pro...The study,also showed that the compound did not in...
...rgeting Pro-Inflammatory,Protein -, GAITHERSBURG, ...mmune, Inc. today announced the publication of pre...mobility group box,protein-1 (HMGB1), a nuclear DN...toimmune diseases such as systemic lupus,erythemat... to be,published in the May 2007 issue of Nature I...
Other Medicine Technology:Aeolus Pharmaceuticals' AEOL 10113 Demonstrates Potential as a,Protector of Healthy Normal Cells from Cancer Radiation Therapy 2Aeolus Pharmaceuticals' AEOL 10113 Demonstrates Potential as a,Protector of Healthy Normal Cells from Cancer Radiation Therapy 3MedImmune Publishes New Data in Nature Immunology Demonstrating The,Role HMGB1 May Play in Systemic Autoimmune Diseases 2MedImmune Publishes New Data in Nature Immunology Demonstrating The,Role HMGB1 May Play in Systemic Autoimmune Diseases 3
(Date:1/8/2009)...t. Jude study could shape new treatments for secon...wswire-USNewswire/ -- Scientists at St. Jude Child...ffective treatment for bacterial pneumonia followi...damycin and azithromycin, which kill bacteria by i...ive than a standard first-line treatment with the ...
(Date:1/8/2009)...owered bad cholesterol more effectively than Zocor...- After nearly a year of review, U.S. health offic...ed use of the controversial cholesterol-lowering d...ation said there was no significant difference in ...ytorin and patients taking the drug Zocor. , Bu...
(Date:1/8/2009)...., Jan. 8 Hanger Orthop...unce that throughout the fourth quarter of 2008 it...ter, Rocky Mountain Orthotic-Prosthetics Center, R... First Coast Orthotics & Prosthetics, and Orth...tions add patient care centers to existing markets...
(Date:1/8/2009)...CISCO, Jan. 8 Medivation...id Hung, M.D., president and chief,executive offi...ealthcare,Conference on Wednesday, January 14, at...s Hotel in San Francisco. , Dr. Hung will p...,development programs for Dimebon for Alzheimer,s ...
Breaking Medicine News(10 mins):Health News:Study Finds More Effective Treatment for Pneumonia Following Influenza 2Health News:Study Finds More Effective Treatment for Pneumonia Following Influenza 3Health News:FDA Backs Cholesterol Drug Vytorin 2Health News:Hanger Orthopedic Group, Inc. Announces Six Acquisitions Totaling $8.9 Million of Annual Net Revenue 2Health News:Medivation Announces Participation in 27th Annual J.P. Morgan Healthcare Conference 2
...’s another reason to include soy in your diet: Res...l cancer. The study reports eating some phytoestro...ly protective among postmenopausal women. The deve...o prolonged exposure to estrogens without exposure...
...erent types of airborne pollens can trigger asthma...lant pollens trigger more emergency hospital admis...m 1995 to 1998 in Madrid. During this time, resear...respiratory illnesses. They also collected data on...
...s that are commonly used to lower cholesterol leve...sease with an unknown cause. The disease, known as...in an enlarged heart that doesn't pump properly. U...e, IDC is not due to a blockage of the coronary ar...
...Peter Safar, a pioneer in emergency medicine who a...resuscitation, died Sunday evening of cancer. He w...burban Pittsburgh, was credited with establishing ...disciplinary intensive care unit. He also develope...
Other Medicine News:Health News:Father of CPR dies at 79 2
... increase in Endoscopic cases it is extremely popu...Surgical Light. This combination affords the surg...to adopt an uncomfortable pose. The Dual Light Sy...toring System. As such the light can be purchased...
...figuration offers all the performance of a major s... for use in Outpatient Settings, Minor Procedure R...wo single lights either side of the OR table is be...combining Flat Screen LCD Monitors with the lights...
A Western Blot Immunassay for the detection of antibodies to primarily anti-myelin associated glycoproteins (anti-MAG) and other glycolipid autoantibodies in human serum.
Triturus® is an open and completely automated ELISA immunoassay analyzer which can perform a variety of different tests on a series of samples and process several batches simultaneously.
Medicine Products: